Male breast cancer differs from female breast cancer in molecular features that affect prognoses and drug responses.

ABSTRACT:

Background

Male breast cancer (MBC) is a rare malignancy with a worse prognosis than female breast cancer (FBC). Current MBC treatment strategies are based on those for FBC. However, molecular differences between MBC and FBC with respect to prognosis and drug responses remain unclear.

Methods

After controlling for confounding factors with propensity score matching (PSM), differences between MBC and FBC were comprehensively analyzed using many types of data: survival, immune microenvironments, sex hormone responses, drug sensitivity, transcriptomes, genomes, epigenomes, and proteomes.

Results

Overall survival (OS) and cancer-specific survival (CSS) were both worse for MBC than for FBC. Differentially expressed mRNAs were enriched in numerous cancer-related functions an

SUBMITTER: Li Y 

PROVIDER: S-EPMC11088352 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature